Turning Point Brands Faces Critical Earnings Test

Investors are watching Turning Point Brands closely as the company prepares to release its third-quarter 2025 financial results this Wednesday. The upcoming earnings report represents a crucial test for the stock following an unexpectedly strong second quarter performance and significantly raised full-year guidance that has heightened market expectations.

Impressive Q2 Results Set High Bar

The company’s previous quarterly performance substantially exceeded analyst projections across multiple key metrics:

• Revenue surged 25.1% to $116.63 million
• Earnings per share reached $0.98 – $0.19 above expectations
• Gross margin expanded to 57.1% – an improvement of 310 basis points
• Modern Oral products generated $30.1 million – representing 26% of total revenue

Market researchers now anticipate third-quarter earnings per share between $0.695 and $0.97, with revenue projections ranging from $110.24 million to $111.42 million. The central question remains whether the company can maintain this impressive momentum.

Diverging Segment Performance

Turning Point Brands is experiencing dramatically different fortunes across its business segments. The Modern Oral division has emerged as the primary growth engine, with Stoker’s product sales volume skyrocketing 59.8% during the first half of 2025 alone. This remarkable expansion contributed an additional $46.1 million to the company’s revenue.

Should investors sell immediately? Or is it worth buying Turning Point Brands?

However, not all segments share this positive trajectory. The Zig-Zag business unit reported a 6.9% revenue decline during the second quarter, highlighting the challenge management faces in offsetting weakness in traditional product categories through innovation and growth in newer segments.

Strong Institutional Support

The investment community continues to demonstrate substantial confidence in Turning Point Brands’ strategic direction. Institutional investors maintain positions representing 96.12% of outstanding shares, with several hedge funds recently increasing their stakes.

Weiss Ratings affirmed a “Buy” recommendation on October 31, while other market analysts have issued “Strong Buy” ratings. The company’s recent dividend payment of $0.075 per share further underscores its financial stability.

All eyes now turn to Wednesday’s earnings release, which will reveal whether the Modern Oral segment’s robust growth can sufficiently compensate for ongoing challenges in the traditional Zig-Zag division.